Filing Flows › Tandem Diabetes Care (TNDM) › Q2 2026
Tandem Diabetes Care (TNDM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Tandem Diabetes Care (TNDM) reported revenue of $255M for the second quarter 2026 (Q2 2026), +6% from a year earlier and +3% from the quarter before. Operating margin was -5.4%, net loss $21.2M (8.3% of revenue).
Tandem Diabetes Care, Q2 2026: revenue $255M (+6% year over year), operating margin -5.4%, net loss $21.2M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $255M | +3% | +6% |
| Operating profit | −$13.8M | — | — |
| Net earnings | −$21.2M | — | — |
| Operating cash flow | −$34.6M | -413% | — |
What changed
Revenue was $254.6M in Q2 2026, up 6% year over year and up 3% from the previous quarter. Supplies and other was the largest line at 55% of revenue. Supplies and other added $11.1M year over year (up 9%), 80% of the total change.
Gross margin was 56.9%, up 4.6 points from Q2 2025. Operating costs exceeded revenue by $13.8M, an operating margin of -5.4%. Operating expenses fell 11% while revenue rose 6%. The quarter ended with a net loss of $21.2M, wider than the previous quarter's $20.4M loss.
Operating cash flow was −$34.6M. Non-cash charges added back $4.5M of depreciation and amortization and $15.7M of share-based compensation. Working capital and other items used $33.7M. Capital expenditures of $4.0M exceeded it, leaving free cash flow of −$38.7M.
Questions
What was Tandem Diabetes Care's revenue in the second quarter 2026?
Tandem Diabetes Care (TNDM) reported revenue of $255M for the second quarter 2026 (Q2 2026), +6% from a year earlier and +3% from the quarter before.
Was Tandem Diabetes Care profitable in the second quarter 2026?
Operating loss was $13.8M (-5.4% of revenue) and net loss $21.2M.